Drs. Rasmussen and Scofield reply

To the Editor:

The cardinal laboratory/pathological features of Sjögren syndrome (SS) are autoantibodies (anti-Ro/SSA and anti-La/SSB) and lymphocytic infiltrate of the salivary glands. The lymphocytic infiltrate is graded by the focus score (FS)1-3, which is the number of foci with ≥ 50 lymphocytes per 4 mm². Much has been published about the clinical and laboratory differences found among Sjögren patients with and without autoantibodies, with the presence of anti-Ro generally associated with more severe disease2,4. However, comparatively few studies have been directed at subjects without a such a biopsy in the past and an average follow-up of almost 6 years5. Thus, the results are likely to be different but complementary. This is, in fact, what we find when reviewing the results of these studies.

However, there is major difference in the analyses. When we compared all FS = 0 subjects to all FS ≥ 1 subjects, irrespective of their anti-Ro status, we continued to find more abnormal ocular staining among those with a positive FS (65.2% vs 49.3%, P = 0.012, OR 1.9, 95% CI 1.2–3.2), as well as a higher incidence of an abnormal Schirmer test (50.1% vs 41.3%, P = 0.0004, OR 1.4–9.2). Thus, objective ocular dryness was less common among those without a lymphocytic infiltrate in the minor salivary glands independent of the presence of anti-Ro. Meanwhile, there was no difference in the ESSDAI biological domain (P = 0.74), supporting previous findings that hypergammaglobulinemia is strongly linked to anti-Ro positivity1,3.

These 2 studies support the notion that there are various subgroups of patients with SS; those that have mainly an autoantibody-driven disease, a second group with active cellular infiltration of target tissues, and a third subset with both lymphocytic glandular infiltration and autoantibodies. Likely, some of the underlying disease mechanisms differ as well — a consideration that may prove relevant for therapeutic choices as well as studies.

The challenges of studying SS are demonstrated in these 2 studies5-6. SS is one of few, if not the only, inflammatory rheumatic disease in which there is easy access to the affected organ; therefore, studies with full sets of data including biopsies are critically important but also difficult to assemble. A prospective inception cohort study has not been reported. So, for now cross-sectional and retrospective studies remain the standard.

Astrid Rasmussen1,2, MD, PhD
R. Hal Scofield3,4,5, MD
1Genes and Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA;
2Dirección de Investigación, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico;
3Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation;
4Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center;
5Oklahoma City Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA.

This work was supported in part by VA Merit Review I51BX001451 as well as National Institutes of Health grants AR053734, AR053483, AI082714, and GM104938.

Address correspondence to Dr. R.H. Scofield, 732 NE 18th Street, Oklahoma City, OK 73104, USA. Email: hal-scofield@omrf.ouhsc.edu.

REFERENCES